Safety and pharmacokinetics of the oral iron chelator SP‐420 in β‐thalassemia

Alì Taher(American University of Beirut Medical Center), Vip Viprakasit(Siriraj Hospital), Ellis J. Neufeld(St. Jude Children's Research Hospital), Keith Pietropaolo(Synta Pharmaceuticals (United States)), Yeşim Aydınok(Ente Ospedaliero Ospedali Galliera), Gregory Berk, Kevin H.M. Kuo(University Health Network), Janet L. Kwiatkowski(Children's Hospital of Philadelphia), Alan R. Cohen(Children's Hospital of Philadelphia), Antoine N. Saliba(Mayo Clinic in Arizona), Patricia J. Giardina(Cornell University), Brenda I. Jeglinski(Synta Pharmaceuticals (United States))
American Journal of Hematology
September 22, 2017
10.1002/ajh.24914
Cited by 15

Related Papers

Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study
|The Lancet|2011|1.3k
Thalassaemia
|The Lancet|2017|763
A Prospective Study of Human Immunodeficiency Virus Type 1 Infection and the Development of AIDS in Subjects with Hemophilia
|New England Journal of Medicine|1989|528
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial
|The Lancet|2015|518
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320